MedPath

Esthesioneuroblastoma: Outcomes After Treatment

Withdrawn
Conditions
Esthesioneuroblastoma, Olfactory
Registration Number
NCT02580136
Lead Sponsor
Ricardo L. Carrau, MD
Brief Summary

The purpose of this study is to collect and organize data into a repository to gather relevant information for future research from patients diagnosed with a rare malignant sinonasal cancer called esthesioneuroblastoma (ENB) and are scheduled to undergo endonasal skull base surgery. Data being collected includes surgical data, demographics, disease presentation, MRI, CT, PET imaging, and post-operative assessments including pathology tests. After surgery, the investigators will collect chemotherapy and radiation data. Participants will also complete quality of life questionnaires at their follow-up visits.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Between the age of 10-80 years
  • Diagnosed with esthesioneuroblastoma
Exclusion Criteria
  • Refusal to participate

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Quality of Lifeup to 120 months after treatment

Anterior Skull Base (ASB); Skull Base Inventory (SBI); Multidimensional Disease Specific Inventory MDS; ASB-Nasal 12; Sino-Nasal Outcome Test (SNOT-20)

Progression-free survival and overall survivalUp to 120 months

Kaplan-Meier survival curves

Secondary Outcome Measures
NameTimeMethod
Length of Hospital Stayup to 120 months
Number of participants with intraoperative complicationsup to 120 months
Number of participants with postoperative complicationsup to 120 months
Time spent in operating roomup to 120 months
MRI imaging evidence of resectionup to 120 months
Surgical Techniqueup to 120 months

Trial Locations

Locations (1)

The Ohio State University

🇺🇸

Columbus, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath